Nubeqa Investor Webinar February 2022

At this event, results from ARASENS, a Phase III study that examined the use of Darolutamide (Nubeqa™) in combination with androgen deprivation therapy (ADT) and chemotherapy versus ADT and chemotherapy alone in patients suffering from metastatic hormone-sensitive prostate cancer (mHSPC), will be presented by the study’s Coordinating Principal Investigator, Matthew Raymond Smith, M.D., Ph.D., Director of the Genitourinary Malignancies Program, Massachusetts General Hospital Cancer Center. Christian Rommel, Head of R&D, Bayer Pharmaceuticals and Robert LaCaze, Head of Oncology, Bayer Pharmaceuticals will put these results into perspective with existing treatment options and discuss how Darolutamide could potentially change the treatment paradigm across various stages of prostate cancer. A presentation will be followed by Q&A.

Friday, February 18, 2022